<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00589771</url>
  </required_header>
  <id_info>
    <org_study_id>674- MED</org_study_id>
    <secondary_id>2007-674MED-ERC</secondary_id>
    <secondary_id>SB-IBS-674</secondary_id>
    <secondary_id>SB-IBS-cytokines-674</secondary_id>
    <nct_id>NCT00589771</nct_id>
  </id_info>
  <brief_title>Saccharomyces Boulardii in Irritable Bowel Syndrome</brief_title>
  <acronym>SB-IBS</acronym>
  <official_title>Clinical and Cytokine Response to Saccharomyces Boulardii Therapy in Diarrhea Dominant Irritable Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aga Khan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biocodex</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aga Khan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Various studies have been conducted in past using different strains of probiotics in
      evaluating IBS symptoms. The results are by no means consistent and the overall impact of
      probiotics in IBS remains unclear. However, recently O'Mahony L et al have shown that
      Bifidobacterium infantis 35624 alleviates symptoms in IBS; this symptomatic response was
      associated with normalization of the ratio of an anti-inflammatory to a proinflammatory
      cytokine (IL-10/IL-12 ratio), suggesting an immune-modulating role for this organism, in this
      disorder.Saccharomyces boulardii is a probiotic yeast that has been successfully used for the
      antibiotic induced diarrhea, prevent relapse of Clostridium difficile and Crohn's disease. It
      ameliorates intestinal injury and inflammation caused by a wide variety of enteric
      pathogens.We therefore plan a Double-blind, randomized, placebo-controlled study to assess
      the effects of Saccharomyces boulardii in improving symptomatology of diarrhea predominant
      IBS and its effect on quality of life. We also plan to assess the changes in the relative
      production of anti-inflammatory interleukin (IL)-10 to proinflammatory cytokines (IL-12, IL-8
      and TNFÎ±).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the efficacy of Saccharomyces boulardii in reducing clinical symptoms, improving cytokines levels and histology features</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the efficacy of Saccharomyces boulardii in improving quality of life and safety of the drug</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Diarrhea Dominant Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsule Saccharomyces boulardii 250 mg TDS for six weeks.
Ispahgula husk 1 Tsf daily after dinner for six weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Capsule Placebo TDS for six weeks.
Ispaghula husk 1 Tsf daily after dinner for six weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saccharomyces boulardii</intervention_name>
    <description>Saccharomyces boulardii one capsule 250mg TDS for 6 weeks
Ispaghula husk 1 Tsf daily after dinner for six weeks</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Enflor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Cap Placebo TDS for six weeks
Ispaghula husk 1 Tsf daily after dinner for six weeks</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diarrhea-predominant IBS satisfying ROME III criteria.

          2. Adults aged 18-70

        Exclusion Criteria:

          1. Pregnant and lactating females

          2. Inflammatory bowel disease and other systemic disease

          3. Patients on anti-diarrheal and antibiotics drugs

          4. Patients with any ongoing infection

          5. Not willing to participate

          6. Allergy to any of Saccharomyces boulardii components

          7. Central venous catheter carriers

          8. Other probiotics e.g., Lactobacillus and Bifidobacterium
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zaigham Abbas, FACG</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aga Khan University HOSPITAL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aga Khan University Hospital</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <zip>74800</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>December 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2008</study_first_posted>
  <last_update_submitted>October 14, 2012</last_update_submitted>
  <last_update_submitted_qc>October 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aga Khan University</investigator_affiliation>
    <investigator_full_name>Zaigham Abbas</investigator_full_name>
    <investigator_title>Consultant Gastroenterologist</investigator_title>
  </responsible_party>
  <keyword>IBS</keyword>
  <keyword>Saccharomyces boulardii</keyword>
  <keyword>probiotics</keyword>
  <keyword>cytokine</keyword>
  <keyword>histology</keyword>
  <keyword>Efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psyllium</mesh_term>
    <mesh_term>Calcium polycarbophil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

